Cover Image

Economic evaluation in genomic and precision medicine /

Economic Evaluation in Genomic and Precision Medicine provides an in-depth examination of essential concepts, protocols and applications of economic evaluation in genomic and precision medicine. Contributions from leading international medical geneticists and health economists compile new ways to ef...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Mitropoulou, Christina (Editor), Wordsworth, Sarah (Editor), Buchanan, James (Editor), Patrinos, George P. (Editor)
Format: eBook
Language:English
Published: London ; San Diego, CA : Academic Press, [2023]
Series:Translational and applied genomics series.
Subjects:
Medical genetics > Economic aspects.
Genomics > Economic aspects.
Precision medicine > Economic aspects.
Medical economics.
Economics, Medical
Génétique médicale > Aspect économique.
Génomique > Aspect économique.
Médecine de précision > Aspect économique.
Économie de la santé.
Medical economics
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Intro
  • Economic Evaluation in Genomic and Precision Medicine
  • Copyright
  • Contents
  • Contributors
  • Preface
  • Chapter 1: Introduction to economic evaluation in health sciences
  • 1.1. Introduction
  • 1.2. Key economic concepts and terminology used in health economics
  • 1.2.1. Budget constraints and demand
  • 1.2.2. Utility
  • 1.2.3. Indifference curves
  • 1.2.4. Social welfare
  • 1.3. Economic evaluation
  • 1.3.1. Rationale for economic evaluation
  • 1.3.2. Types of economic evaluation
  • 1.3.2.1. The extra-welfarist approach to economic evaluation
  • 1.3.2.2. The welfarist approach to economic evaluation
  • 1.3.2.3. Welfarism versus extra-welfarism: Which approach should be used?
  • 1.4. Concluding remarks
  • References
  • Chapter 2: Foundations of pharmacogenomics and personalized medicine
  • 2.1. Introduction
  • 2.2. Implementing pharmacogenomics into clinical care
  • 2.2.1. Pharmacogenomics for cancer therapeutics
  • 2.2.2. Pharmacogenomics for drug treatment of cardiovascular diseases
  • 2.2.3. Pharmacogenomics for psychiatric diseases
  • 2.3. Electronic tools for translating genomic findings into a clinically meaningful format
  • 2.4. Assessing the ethical, societal, and financial aspects of personalized medicine
  • 2.4.1. Ethical and legal issues
  • 2.4.2. Raising genomics awareness among healthcare professionals and the general public
  • 2.4.3. Economic evaluation of personalized medicine interventions
  • 2.5. Large-scale personalized medicine implementation efforts worldwide
  • 2.6. Conclusions and future perspectives
  • Acknowledgments
  • References
  • Chapter 3: Economic evaluation of genome-guided treatment in oncology
  • 3.1. Introduction
  • 3.2. Methodological challenges
  • 3.3. The inseparability of test and treatment
  • 3.4. Value of testing
  • 3.5. Cost-effectiveness comparator
  • 3.6. Pricing and reimbursement.
  • 3.7. Conclusion
  • References
  • Chapter 4: Economic evaluation of rare diseases and the diagnostic odyssey
  • 4.1. Introduction
  • 4.2. Genomics and rare diseases
  • 4.2.1. Diagnostic odyssey
  • 4.2.2. Opportunity for genomics
  • 4.2.2.1. Clinical and healthcare system implications of genomic testing
  • 4.3. Economic evaluations of genomics in rare diseases
  • 4.3.1. Step 1: Determine comparators and study design
  • 4.3.1.1. Selected literature examples
  • Using a trial cohort to compare testing methods-Sagoo et al. (2015)
  • Using a retrospective cohort to estimate impact of testing sequence-Schofield et al. (2017)
  • Comparing two different genomic approaches in a retrospective cohort-Hayeems et al. (2017)
  • 4.3.1.2. Recommendations
  • 4.3.2. Step 2: Estimate health and non-health outcomes
  • 4.3.2.1. Selected literature examples
  • Cost per additional diagnosis-Vissers et al. (2017)
  • Cost per additional diagnosis and changes in management-Soden et al. (2014)
  • Cases avoided through testing-Azimi et al. (2016)
  • How is personal utility estimated?
  • 4.3.2.2. Recommendations
  • 4.3.3. Step 3: Estimate costs
  • 4.3.3.1. Selected literature examples
  • Costing surveys for laboratory tests-Wordsworth et al. (2007)
  • Bottom-up microcosting of clinical activity-Tsiplova et al. (2017)
  • 4.3.3.2. Recommendations
  • 4.3.4. Step 4: Estimate relationship between costs and outcomes
  • 4.3.4.1. Selected literature examples
  • Cost-effectiveness, net benefit, and personal utility-Regier et al. (2010)
  • Cost per QALY among relatives of affected individuals-Perez et al. (2011)
  • Cost per additional diagnosis achieved-Tan et al. (2017)
  • Costs and consequences of technology adoption-Córdoba et al. (2018)
  • 4.3.4.2. Recommendations
  • 4.4. Conclusion
  • Acknowledgment
  • References.
  • Chapter 5: Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions
  • 5.1. Introduction
  • 5.2. Economic evaluation of adverse drug reaction-related human leukocyte antigen genotyping, its guidelines, and current ...
  • 5.2.1. Abacavir-induced hypersensitivity reaction
  • 5.2.1.1. Health economic evidence for HLA-B*57:01 screening for HIV
  • 5.2.2. Allopurinol-induced hypersensitivity reaction
  • 5.2.2.1. Health economic evidence for HLA-B*58:01 screening before prescribing allopurinol
  • 5.2.3. Carbamazepine-induced hypersensitivity reaction
  • 5.3. Conclusions
  • References
  • Chapter 6: Economic evaluation of personalized medicine interventions in medium- and low-income countries with poor pro
  • 6.1. Introduction
  • 6.2. Implementing personalized medicine interventions beyond high-income countries: Setting the scene
  • 6.2.1. Challenges in low-income and lower middle-income countries outside Europe
  • 6.2.2. Challenges in upper middle-income countries in Europe
  • 6.3. Examples of economic evaluations of personalized medicine interventions in medium- and low-income countries
  • 6.3.1. Anticoagulation and antiplatelet therapies
  • 6.3.2. Antidepressants
  • 6.3.3. Allopurinol
  • 6.3.4. Human papillomavirus testing
  • 6.4. A generic model as tool for measuring cost-effectiveness of personalized medicine interventions in medium- and low-i ...
  • 6.5. Conclusion and future perspectives
  • Acknowledgments
  • References
  • Chapter 7: Theoretical models for economic evaluation in genomic and personalized medicine
  • 7.1. Introduction
  • 7.2. The genome economics model
  • 7.3. Generalization of the genome economics model
  • 7.4. Perspectives
  • References
  • Chapter 8: Using ``big data´´ for economic evaluations in genomics
  • 8.1. Introduction.
  • 8.2. Using ``big data´´ for the economic evaluation of genomic tests
  • 8.3. Analytics for omics data
  • 8.4. Difficulties in using ``big data´´ in for economic evaluation of sequencing tests
  • 8.4.1. Data collection challenges
  • 8.4.1.1. Small number of observations
  • 8.4.1.2. Insufficient outcomes data for cost-effectiveness analysis
  • 8.4.2. Data management challenges
  • 8.4.2.1. Data linkage
  • 8.4.2.2. Large number of zero observations
  • 8.4.2.3. Difficulties in setting up big datasets for economic evaluation
  • 8.4.3. Data analysis challenges
  • 8.4.3.1. Selection bias and confounding
  • 8.4.3.2. Lack of a counterfactual
  • 8.4.4. Identifying key challenges
  • 8.5. Conclusions
  • References
  • Further reading
  • Chapter 9: Assessing the stakeholder environment and views towards implementation of personalized medicine in a healt
  • 9.1. Introduction
  • 9.2. Identifying stakeholders in personalized medicine
  • 9.3. Eliciting and analyzing stakeholder views and opinions related to personalized medicine
  • 9.4. Implementing stakeholder analysis in genomic and personalized medicine: An example from the preliminary assessment o ...
  • 9.5. Defining opportunities and threats when implementing genomic and personalized medicine in Greece
  • 9.6. Concluding remarks
  • Acknowledgments
  • References
  • Chapter 10: Feasibility for pricing, budget allocation, and reimbursement of personalized medicine interventions
  • 10.1. Introduction
  • 10.2. Institutions involved in pricing and reimbursement
  • 10.3. Coverage, pricing, and reimbursement strategies for genomic testing services
  • 10.4. A proposed strategy for pricing and reimbursement in personalized medicine
  • 10.4.1. Ensure access to essential genomic testing services for all at acceptable and affordable prices for the healthcar.
  • 10.4.2. Establish a common and centralized regulation to ensure safety, efficacy, quality, and fairness, while allowing s ...
  • 10.4.3. Implementation of genomic tests and information by physicians, according to patient needs and clinical utility/ac ...
  • 10.4.4. Invest in the research of personalized medicine, evaluate novel and existing diagnostic procedures, and monitor p ...
  • 10.5. Restrictions and concerns
  • 10.6. Conclusions
  • References
  • Index.